Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Assembly Biosciences, Inc. (NASDAQ:ASMB) has been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $42.75.

A number of brokerages recently weighed in on ASMB. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Assembly Biosciences in a research note on Monday, May 4th. Wall Street Zen upgraded Assembly Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Sunday, March 29th. Guggenheim upped their price objective on Assembly Biosciences from $39.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday, April 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Monday, April 20th.

Institutional Investors Weigh In On Assembly Biosciences

A number of hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE increased its position in Assembly Biosciences by 6,382.7% during the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 3,319 shares in the last quarter. Seven Fleet Capital Management LP purchased a new stake in Assembly Biosciences in the fourth quarter valued at about $147,000. Acadian Asset Management LLC raised its stake in Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 6,823 shares during the last quarter. Charles Schwab Investment Management Inc. purchased a new stake in Assembly Biosciences in the fourth quarter valued at about $228,000. Finally, Virtus Investment Advisers LLC purchased a new stake in Assembly Biosciences in the fourth quarter valued at about $251,000. 19.92% of the stock is currently owned by hedge funds and other institutional investors.

Assembly Biosciences Trading Up 2.9%

Shares of ASMB stock opened at $31.72 on Thursday. Assembly Biosciences has a twelve month low of $12.11 and a twelve month high of $39.71. The stock has a market capitalization of $504.03 million, a price-to-earnings ratio of -288.34 and a beta of 1.08. The stock has a fifty day simple moving average of $28.75 and a two-hundred day simple moving average of $30.61.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.11. The firm had revenue of $8.21 million during the quarter, compared to analysts’ expectations of $9.27 million. Assembly Biosciences had a negative return on equity of 4.21% and a negative net margin of 8.98%. Research analysts predict that Assembly Biosciences will post -0.93 EPS for the current fiscal year.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.